WEST CHESTER, Ohio, Feb. 12 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana Point, California on Wednesday, February 20th at 2:00 p.m. PT.
A live web cast and recording of the presentation will be available for 30 days following the presentation on AtriCure's Investor Relations page at http://www.atricure.com.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(R) bipolar ablation system,
including the new Isolator Synergy(TM) ablation clamps and the AtriCure
multifunctional bipolar Pen, for the ablation, or destruction, of cardiac
tissue during surgical procedures. Additionally, the FDA has cleared the
AtriCure Pen for temporary pacing, sensing, stimulating and recording
during the evaluation of cardiac arrhythmias. To date, the FDA has not
cleared or approved AtriCure's products for the treatment of AF. AtriCure's
left atrial appendage clip system has not been approved for commercial use.
It is currently being used in clinical evaluations in Europe.
Julie A. Piton
Vice President and Chief Financial Officer
|SOURCE AtriCure, Inc.|
Copyright©2008 PR Newswire.
All rights reserved